Literature DB >> 23109517

Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.

Peter Ong1, Simon Greulich, Julia Schumm, Maik Backes, Martin Kaufmann, Sabine Bode-Erdmann, German Ott, Holger Hebart, Heiko Mahrholdt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23109517     DOI: 10.1161/CIRCULATIONAHA.112.128348

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

Review 1.  Pazopanib in sarcomas: expanding the PALETTE.

Authors:  Breelyn A Wilky; Christian F Meyer; Jonathan C Trent
Journal:  Curr Opin Oncol       Date:  2013-07       Impact factor: 3.645

2.  CT-morphologic and CT-textural patterns of response in inoperable soft tissue sarcomas treated with pazopanib-a preliminary retrospective cohort study.

Authors:  Michael Esser; Cristopher Kloth; Wolfgang M Thaiss; Christian P Reinert; Mareen S Kraus; Gabriel Cc Gast; Marius Horger
Journal:  Br J Radiol       Date:  2019-09-19       Impact factor: 3.039

3.  Surgical Management of Massive Pericardial Effusion and Predictors for Development of Constrictive Pericarditis in a Resource Limited Setting.

Authors:  Emeka B Kesieme; Peter O Okokhere; Christopher Ojemiega Iruolagbe; Angela Odike; Clifford Owobu; Theophilus Akhigbe
Journal:  Adv Med       Date:  2016-07-19

4.  Primary cardiac angiosarcoma: a prolonged response to surgical resection followed by concurrent chemoradiotherapy with docetaxel.

Authors:  Youngwoo Jang; Joonhwan Kim; Jung Woo Shim; Eun Young Kim; Jungkeun Moon; Jungsuk An; Yang Bin Jeon; Kyu Chan Lee; Hee Kyung Ahn
Journal:  Springerplus       Date:  2016-05-17

5.  An unusual cause of a large fibrinous pericardial effusion.

Authors:  Noleen Chengetai Tembani-Munyandu; Rudo Makunike-Mutasa; Leolin Katsidzira; Andrew Chinogureyi
Journal:  Cardiovasc J Afr       Date:  2015-05-23       Impact factor: 1.167

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.